Simulations Plus
Open
$16.30
Prev. Close
$16.29
High
$16.34
Low
$16.26
Market Snapshot
$328.79M
-5.2
0.41
$74.44M
213
Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The company is headquartered in Research Triangle Park, North Carolina and currently employs 212 full-time employees. The firm helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The firm's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The company is headquartered in Research Triangle Park, North Carolina and currently employs 212 full-time employees. The firm helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The firm's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Recently from Cashu
Rosen Law Probes Simulations Plus Over Q3 Sales and Preliminary Revenue Disclosures
Investigation Questions Simulations Plus’ Sales Disclosures and Demand Outlook Rosen Law Firm is investigating potential securities claims accusing Simulations Plus Inc. of issuing materially misleadi…
Rosen Law Opens Class-Action Probe into Simulations Plus Over Alleged Misleading Q3 2025 Disclosures
Legal Probe Targets Simulations Plus’ Disclosures Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc., alleging the company issued materially misleading business…
Rosen Law Investigates Simulations Plus Over Alleged Misleading Sales Disclosures
Legal Inquiry Opens Into Simulations Plus' Sales Disclosures Rosen Law Firm is opening an investigation into Simulations Plus Inc. over allegations that the company issues materially misleading busine…
Simulations Plus Faces Legal Investigation Over Alleged Misleading Information Impacting Shareholders
### Legal Scrutiny Intensifies for Simulations Plus Amid Allegations of Misleading Information Simulations Plus, Inc. faces a significant legal challenge as the Rosen Law Firm initiates an investigati…